Neoadjuvant immunotherapy in early-stage NSCLC: navigating biomarker dilemmas and special population challenges

被引：0

作者：

Chen, Tong ^{[1
]}

Liu, Fang ^{[1
]}

机构：

[1] Harbin Med Univ, Dept Med Oncol, Canc Hosp, Harbin, Peoples R China

来源：

LUNG CANCER | 2025年 / 204卷

关键词：

NSCLC; Neoadjuvant immunotherapy; Immune checkpoint inhibitors; Tumor microenvironment; Biomarkers; Multicohomology; CELL LUNG-CANCER; MOLECULAR RESIDUAL DISEASE; SINGLE-ARM; OPEN-LABEL; PATHOLOGICAL RESPONSE; PLUS CHEMOTHERAPY; EFFICACY; MULTICENTER; TRIAL; IMMUNOCHEMOTHERAPY;

D O I：

10.1016/j.lungcan.2025.108588

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Neoadjuvant immunotherapy has shown impressive outcomes in treating non-small cell lung cancer (NSCLC) recently due to advancements in immune checkpoint inhibitors (ICIs) research. Neoadjuvant immunotherapy can lower the tumor load, raise the complete surgical (R0) resection rate, and improve clinical outcomes by alleviating the immune system repression caused by tumor cells. This review provides a comprehensive evaluation of neoadjuvant immunotherapy in NSCLC, focusing on: (1) its safety and efficacy profiles, (2) the most recent clinical trial evidence, and (3) critical unresolved challenges including predictive biomarker development, management of driver mutation-positive patients, chronic obstructive pulmonary disease (COPD) comorbidity considerations, and its application in stage III-IVA (oligometastatic) disease. Furthermore, we explore future research directions to optimize neoadjuvant immunotherapy approaches for resectable NSCLC, aiming to guide clinical practice and investigation.

引用

页数：11

共 90 条

[1] MYC activation impairs cell-intrinsic IFNy signaling and confers resistance to anti-PD1/PD-L1 therapy in lung cancer [J].

Alburquerque-Bejar, Juan J. ;

Navajas-Chocarro, Pablo ;

Saigi, Maria ;

Ferrero-Andres, Ana ;

Morillas, Juan M. ;

Vilarrubi, Andrea ;

Gomez, Antonio ;

Mate, JoseL. ;

Munoz-Marmol, Ana M. ;

Romero, Octavio A. ;

Blecua, Pedro ;

Davalos, Veronica ;

Esteller, Manel ;

Pros, Eva ;

Llabata, Paula ;

Torres-Diz, Manuel ;

Esteve-Codina, Anna ;

Sanchez-Cespedes, Montse .

CELL REPORTS MEDICINE, 2023, 4 (04)

[2] Efficacy, Safety, and Influence on the Tumor Microenvironment of Neoadjuvant Pembrolizumab plus Ramucirumab for PD-L1-Positive NSCLC: A Phase II Trial (EAST ENERGY) [J].

Aokage, Keiju ;

Koyama, Shohei ;

Kumagai, Shogo ;

Nomura, Kotaro ;

Shimada, Yoshihisa ;

Yoh, Kiyotaka ;

Wakabayashi, Masashi ;

Fukutani, Miki ;

Furuya, Hideki ;

Miyoshi, Tomohiro ;

Tane, Kenta ;

Samejima, Joji ;

Taki, Tetsuro ;

Hayashi, Takuo ;

Matsubayashi, Jun ;

Ishii, Genichiro ;

Nishikawa, Hiroyoshi ;

Ikeda, Norihiko ;

Tsuboi, Masahiro .

CLINICAL CANCER RESEARCH, 2024, 30 (24) :5584-5592

[3] Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non-Small-Cell Lung Cancer [J].

Auperin, Anne ;

Le Pechoux, Cecile ;

Rolland, Estelle ;

Curran, Walter J. ;

Furuse, Kiyoyuki ;

Fournel, Pierre ;

Belderbos, Jose ;

Clamon, Gerald ;

Ulutin, Hakki Cuneyt ;

Paulus, Rebecca ;

Yamanaka, Takeharu ;

Bozonnat, Marie-Cecile ;

Uitterhoeve, Apollonia ;

Wang, Xiaofei ;

Stewart, Lesley ;

Arriagada, Rodrigo ;

Burdett, Sarah ;

Pignon, Jean-Pierre .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (13) :2181-2190

[4] Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer [J].

Awad, Mark M. ;

Forde, Patrick M. ;

Girard, Nicolas ;

Spicer, Jonathan ;

Wang, Changli ;

Lu, Shun ;

Mitsudomi, Tetsuya ;

Felip, Enriqueta ;

Broderick, Stephen R. ;

Swanson, Scott J. ;

Brahmer, Julie ;

Kerr, Keith ;

Saylors, Gene B. ;

Chen, Ke-Neng ;

Gharpure, Vishwanath ;

Neely, Jaclyn ;

Balli, David ;

Hu, Nan ;

Pulla, Mariano Provencio .

JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (12) :1453-1462

[5]

Bar J, 2019, J CLIN ONCOL, V37

[6] Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data [J].

Burdett, Sarah ;

Rydzewska, Larysa H. M. ;

Tierney, Jayne F. ;

Auperin, Anne ;

Le Pechoux, Cecile ;

Le Chevalier, Thierry ;

Pignon, Jean-Pierre .

LANCET, 2014, 383 (9928) :1561-1571

[7] Tumor microenvironment features decipher the outperformance of neoadjuvant immunochemotherapy over chemotherapy in resectable non-small cell lung cancer [J].

Cai, Wenhan ;

Jing, Miao ;

Gu, Yajun ;

Bei, Ting ;

Zhao, Xiaochen ;

Chen, Shiqing ;

Wen, Jiaxin ;

Gao, Jie ;

Wu, Chongchong ;

Xue, Zhiqiang .

FRONTIERS IN IMMUNOLOGY, 2022, 13

[8] Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy [J].

Casarrubios, Marta ;

Cruz-Bermudez, Alberto ;

Nadal, Ernest ;

Insa, Amelia ;

Garcia Campelo, Maria del Rosario ;

Lazaro, Martin ;

Domine, Manuel ;

Majem, Margarita ;

Rodriguez-Abreu, Delvys ;

Martinez-Marti, Alex ;

de Castro-Carpeno, Javier ;

Cobo, Manuel ;

Lopez-Vivanco, Guillermo ;

Del Barco, Edel ;

Bernabe Caro, Reyes ;

Vinolas, Nuria ;

Barneto Aranda, Isidoro ;

Viteri, Santiago ;

Massuti, Bartomeu ;

Barquin, Miguel ;

Laza-Briviesca, Raquel ;

Sierra-Rodero, Belen ;

Parra, Edwin R. ;

Sanchez-Espiridion, Beatriz ;

Rocha, Pedro ;

Kadara, Humam ;

Wistuba, Ignacio I. ;

Romero, Atocha ;

Calvo, Virginia ;

Provencio, Mariano .

CLINICAL CANCER RESEARCH, 2021, 27 (21) :5878-5890

[9] Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer [J].

Cascone, Tina ;

Weissferdt, Annikka ;

Godoy, Myrna C. B. ;

William, William N., Jr. ;

Leung, Cheuk H. ;

Lin, Heather Y. ;

Basu, Sreashi ;

Yadav, Shalini S. ;

Pataer, Apar ;

Mitchell, Kyle G. ;

Khan, Md Abdul Wadud ;

Shi, Yushu ;

Haymaker, Cara ;

Solis, Luisa M. ;

Parra, Edwin R. ;

Kadara, Huam ;

Wistuba, Ignacio I. ;

Sharma, Padmanee ;

Allison, James P. ;

Ajami, Nadim J. ;

Wargo, Jennifer A. ;

Jenq, Robert R. ;

Gibbons, Don L. ;

Lee, J. Jack ;

Swisher, Stephen G. ;

Vaporciyan, Araa ;

Heymach, John, V ;

Sepesi, Boris .

NATURE COMMUNICATIONS, 2021, 12 (01)

[10] Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial [J].

Cascone, Tina ;

William, William N., Jr. ;

Weissferdt, Annikka ;

Leung, Cheuk H. ;

Lin, Heather Y. ;

Pataer, Apar ;

Godoy, Myrna C. B. ;

Carter, Brett W. ;

Federico, Lorenzo ;

Reuben, Alexandre ;

Khan, Md Abdul Wadud ;

Dejima, Hitoshi ;

Francisco-Cruz, Alejandro ;

Parra, Edwin R. ;

Solis, Luisa M. ;

Fujimoto, Junya ;

Tran, Hai T. ;

Kalhor, Neda ;

Fossella, Frank V. ;

Mott, Frank E. ;

Tsao, Anne S. ;

Blumenschein, George, Jr. ;

Le, Xiuning ;

Zhang, Jianjun ;

Skoulidis, Ferdinandos ;

Kurie, Jonathan M. ;

Altan, Mehmet ;

Lu, Charles ;

Glisson, Bonnie S. ;

Byers, Lauren Averett ;

Elamin, Yasir Y. ;

Mehran, Reza J. ;

Rice, David C. ;

Walsh, Garrett L. ;

Hofstetter, Wayne L. ;

Roth, Jack A. ;

Antonoff, Mara B. ;

Kadara, Humam ;

Haymaker, Cara ;

Bernatchez, Chantale ;

Ajami, Nadim J. ;

Jenq, Robert R. ;

Sharma, Padmanee ;

Allison, James P. ;

Futreal, Andrew ;

Wargo, Jennifer A. ;

Wistuba, Ignacio I. ;

Swisher, Stephen G. ;

Lee, J. Jack ;

Gibbons, Don L. .

NATURE MEDICINE, 2021, 27 (03) :504-+

← 1 2 3 4 5 6 7 8 9 →